Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for four new non-executive employees. The Compensation Committee approved grants covering 23,875 shares of Puma common stock on April 1, 2025.
The awards, granted under Puma's 2017 Employment Inducement Incentive Award Plan, will vest over three years. One-third of the shares will vest on the first anniversary (April 1, 2025), followed by one-sixth vesting every six months thereafter, contingent on continued employment. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di premi in azioni riservate per quattro nuovi dipendenti non esecutivi. Il Comitato per la Compensazione ha approvato l'assegnazione di 23.875 azioni di azioni ordinarie Puma il 1° aprile 2025.
I premi, concessi nell'ambito del Piano di Incentivazione all'Occupazione del 2017 di Puma, matureranno nell'arco di tre anni. Un terzo delle azioni maturerà al primo anniversario (1° aprile 2025), seguito da un sesto delle azioni che maturerà ogni sei mesi successivamente, a condizione di continuare l'impiego. Questi premi sono stati concessi come incentivi all'occupazione in conformità con Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) ha anunciado la aprobación de premios en unidades de acciones restringidas para cuatro nuevos empleados no ejecutivos. El Comité de Compensación aprobó la concesión de 23,875 acciones de acciones ordinarias de Puma el 1 de abril de 2025.
Los premios, otorgados bajo el Plan de Incentivos de Empleo de 2017 de Puma, se consolidarán durante tres años. Un tercio de las acciones se consolidará en el primer aniversario (1 de abril de 2025), seguido de un sexto que se consolidará cada seis meses a partir de entonces, condicionado a la continuación del empleo. Estas concesiones se realizaron como incentivos de empleo en cumplimiento con Nasdaq Listing Rule 5635(c)(4).
푸마 바이오테크놀로지 (NASDAQ: PBYI)는 네 명의 비임원 직원에 대한 유도 제한 주식 단위 수당 승인을 발표했습니다. 보상 위원회는 2025년 4월 1일 푸마 보통주 23,875주에 대한 수여를 승인했습니다.
이 수당은 푸마의 2017년 고용 유도 인센티브 수여 계획에 따라 부여되며, 3년에 걸쳐 발생합니다. 1주년(2025년 4월 1일)에 3분의 1이 발생하며, 이후 매 6개월마다 6분의 1이 발생하게 되며, 계속 고용되는 조건입니다. 이 수여는 Nasdaq Listing Rule 5635(c)(4)에 따라 고용 유도로 제공되었습니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation de l'octroi d'unités d'actions restreintes en tant qu'incitation pour quatre nouveaux employés non exécutifs. Le Comité de Rémunération a approuvé l'octroi de 23 875 actions ordinaires de Puma le 1er avril 2025.
Les récompenses, accordées dans le cadre du Plan d'Incitation à l'Emploi de 2017 de Puma, seront acquises sur une période de trois ans. Un tiers des actions sera acquis lors du premier anniversaire (1er avril 2025), suivi d'un sixième acquis tous les six mois par la suite, sous réserve de la poursuite de l'emploi. Ces attributions ont été faites comme incitations à l'emploi conformément à Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) hat die Genehmigung von Anreizen in Form von beschränkten Aktienoptionen für vier neue nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte am 1. April 2025 die Vergabe von 23.875 Aktien an Puma-Stammaktien.
Die Auszeichnungen, die im Rahmen des Anreizplans für die Beschäftigung von 2017 von Puma gewährt werden, werden über drei Jahre verteilt. Ein Drittel der Aktien wird am ersten Jahrestag (1. April 2025) fällig, gefolgt von einem Sechstel, das alle sechs Monate danach fällig wird, vorausgesetzt, die Beschäftigung wird fortgesetzt. Diese Zuwendungen wurden als Beschäftigungsanreize gemäß Nasdaq Listing Rule 5635(c)(4) gewährt.
- Company continues to attract new talent with equity compensation
- Potential dilution of existing shareholders from 23,875 new shares
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, April 1, 2025, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402524183/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
How many shares are included in PBYI's latest inducement stock awards?
What is the vesting schedule for PBYI's April 2025 restricted stock unit awards?
How many new employees received PBYI's April 2025 stock awards?
Under which plan were PBYI's April 2025 inducement awards granted?
